MiNK Therapeutics (NASDAQ:INKT) Director Sells $19,140.00 in Stock

MiNK Therapeutics, Inc. (NASDAQ:INKT) Director Barbara Ryan sold 1,500 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $12.76, for a total transaction of $19,140.00. Following the transaction, the director directly owned 21,969 shares in the company, valued at $280,324.44. The trade was a 6.39% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Barbara Ryan also recently made the following trade(s):

• On Tuesday, March 10th, Barbara Ryan sold 1,300 shares of MiNK Therapeutics stock. The shares were sold at an average price of $15.40, for a total transaction of $20,020.00.
• On Monday, March 9th, Barbara Ryan sold 200 shares of MiNK Therapeutics stock. The shares were sold at an average price of $10.17, for a total transaction of $2,034.00.

MiNK Therapeutics Stock Performance

Shares of INKT opened at $11.87 on Monday. The company’s 50 day moving average price is $11.41 and its 200 day moving average price is $11.37. MiNK Therapeutics, Inc. has a 52 week low of $6.80 and a 52 week high of $76.00. The company has a market capitalization of $59.11 million, a PE ratio of -4.18 and a beta of 0.47.

MiNK Therapeutics (NASDAQ:INKT) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.57) EPS for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.20. On average, equities analysts forecast that MiNK Therapeutics, Inc. will post -2.75 earnings per share for the current fiscal year.

Institutional Trading of MiNK Therapeutics

An institutional investor recently raised its position in MiNK Therapeutics stock. Geode Capital Management LLC lifted its position in MiNK Therapeutics, Inc. (NASDAQ:INKT) by 11.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 14,247 shares of the company’s stock after buying an additional 1,441 shares during the quarter. Geode Capital Management LLC owned about 0.30% of MiNK Therapeutics worth $159,000 as of its most recent filing with the Securities and Exchange Commission. 2.87% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have commented on INKT. HC Wainwright reissued a “buy” rating and issued a $35.00 target price on shares of MiNK Therapeutics in a research report on Monday, May 18th. Wall Street Zen raised shares of MiNK Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Finally, Weiss Ratings raised shares of MiNK Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, May 27th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $35.00.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.